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Abstract
Background and aims
In the Nordic countries (Denmark, Finland, Iceland, Norway, Sweden), the prevalence of
chronic hepatitis C virus (HCV) infection is relatively low in the general population, but is
much higher among people who inject drugs (PWID). We conducted an exploratory study to
investigate the extent to which these countries have policies supporting key elements of the
public health response that is necessary to achieve the global goal of eliminating HCV as a
public health threat.
Methods
Fourteen stakeholders representing government agencies, medical societies, and civil soci-
ety organisations (CSOs) in the Nordic countries completed a cross-sectional online survey
that included 21 policy questions related to national coordination, prevention, testing, link-
age to care, and treatment. We summarised the findings in a descriptive analysis, and noted
discrepant responses from stakeholders within the same country.
Results
Stakeholders reported that three of the five study countries have national viral hepatitis strat-
egies, while only Iceland has a national HCV elimination goal. The availability of harm reduc-
tion services varies, with opioid substitution therapy provided for the general population
throughout all countries, but not needle and syringe programmes. No country has access to
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anonymous HCV testing in all parts of the country. National HCV treatment guidelines are
available in all countries except Finland, and all countries provide publicly funded direct-act-
ing antiviral treatment. Disagreement regarding policies was observed across countries,
and CSOs were the stakeholder group that most frequently answered survey questions
incorrectly.
Conclusion
The Nordic region as a whole has not consistently expressed its commitment to tackling
HCV, despite the existence of large HCV epidemics among PWID in these countries. Stake-
holder alignment and an established elimination goal with an accompanying strategy and
implementation plan should be recognised as the basis for coordinated national public
health efforts to achieve HCV elimination in the Nordic region and elsewhere.
Introduction
An estimated 71 million people worldwide have chronic hepatitis C virus (HCV) infection,
including 14 million people in the World Health Organization (WHO) European Region.
[1,2] In this region, HCV causes more than 100,000 deaths annually. [3] Nearly 3.3 million
people in the countries of the European Union are living with chronic HCV infection. [4] Peo-
ple who inject drugs (PWID), including those who inject currently and those who have done
so in the past, are the primary group affected by HCV in Europe. The incidence and prevalence
of HCV infection remain high among PWID in most countries, while access to prevention
and harm reduction services varies widely. [3,5–7] Approximately 43% of the 1.2 million
PWID in the European Union/European Free Trade Association region have HCV RNA,
which indicates active HCV infection. [8] PWID worldwide have high incarceration rates, and
injection drug use is common in prison settings. [9,10] For these and other reasons, the HCV
disease burden is likely to be large among prison populations worldwide. [11] Experts have
called for European countries to prioritise the management of HCV infection among PWID
through policies and guidelines specifically targeting this population. [3,5,12–16]
The five Nordic countries (Denmark, Finland, Iceland, Norway and Sweden) all have
chronic HCV prevalence levels well below 1% in the general population, and the estimated
numbers of chronic HCV cases in these countries collectively total only 100,000. [1] However,
the disease burden is highly concentrated in PWID populations. In Denmark, for example,
68% to 75% of people living with chronic HCV infection in 2014 acquired the disease by shar-
ing injecting drug equipment. [17] In Sweden, 65% of new cases of HCV infection reported to
the authorities are attributable to the sharing of injecting drug equipment. [18] In Iceland,
while the estimated prevalence of chronic HCV infection is 0.3%, 85% of cases are among peo-
ple with a history of injecting drug use. [19] In 2015, Finland had 23,000 chronic HCV cases, a
figure representing 0.5% of the country’s total population. [20] Approximately half of these
cases are active injecting drug users. [21]
In 2016, WHO Member States adopted the goal of eliminating HCV as a major public
health threat by 2030, defining this as an 80% reduction in new chronic infections and a 65%
reduction in mortality. WHO also identified a series of “priority actions” for combating viral
hepatitis and called on countries to implement the actions that speak to specific country-level
priorities. [22] There is scarce published information on how the Nordic countries are address-
ing HCV at the policy level, apart from a 2016 description of Iceland’s national treatment-as-
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prevention campaign on the website clinicaltrials.gov. [23] Two central sources of information
on national responses to HCV, the 2013 Global policy report on the prevention and control of
viral hepatitis in WHOMember States [24] and the 2014 Global community hepatitis policy
report, [25] contain limited information from the Nordic countries, and furthermore, it is not
known whether this information is still current. Thus, it is not possible to ascertain the extent
to which the Nordic countries are prepared to move toward HCV elimination.
We sought to examine the HCV policy landscape in Denmark, Finland, Iceland, Norway
and Sweden in order to inform the ongoing discourse about how Nordic governments should
address this disease. In recognition of previous disagreements among different types of stake-
holders regarding national viral hepatitis policies, [26] the study design called for information
to be gathered from representatives of governments, medical societies and civil society organi-
sations (CSOs).
Methods
We developed a cross-sectional, English-language survey through a two-step process in 2016.
We conducted desk research to identify the most notable HCV policy issues facing national
governments generally and the governments of the Nordic countries particularly. We then
drafted survey questions to reflect these issues and shared them with the Hep-Nordic study
group, which is comprised of either one or two viral hepatitis experts from each of the five
study countries. Multiple rounds of input from Hep-Nordic study group members led to
extensive revisions over a period of five months, until both the study group and the research
team found the final survey questions to be suitable for capturing the relevant policy informa-
tion. We piloted the study instrument to three individuals before the start of the study. Two of
them lived in Hep-Nordic study countries and were knowledgeable about their countries’
responses to viral hepatitis.
In consultation with the Hep-Nordic study group, we used a purposive sampling process
intended to identify four stakeholders per country representing four categories: ministries of
health or similarly relevant government agencies, hepatitis patient groups, drug user groups
and national medical societies. Formal sample size calculations were not appropriate for this
study design due to its exploratory nature. Before beginning the enrolment process, we
decided that Hep-Nordic study group members would be eligible to serve also as survey
respondents, as we anticipated the potential difficulty of identifying an adequate number of
suitable survey respondents, given the relatively small size of the stakeholder communities in
some Nordic countries. Ultimately, two individuals served as both study group members and
study participants. The sampling process identified a total of 17 stakeholders, three fewer than
were sought. We were unable to make contact with anyone who could represent the following
types of stakeholders: a hepatitis patient group in Iceland, a drug user group in Iceland, and a
drug user group in Norway.
We created and managed the final survey (S1 Appendix) using the web-based electronic
data collection tool Research Electronic Data Capture (REDCap), [27] hosted online by the
Centre for Health and Infectious Disease Research (CHIP), Division of Infectious Diseases,
Rigshospitalet, University of Copenhagen, Denmark. We invited the selected key stakeholders
to complete the survey online using a customised survey link auto-generated by the REDCap
system and distributed to each individual via email. Data were collected in October–November
2016.
The survey contained 21 HCV policy questions organised into four domains: national coor-
dination (four items), prevention (four items), testing and linkage to care (six items) and treat-
ment (seven items). Some questions also had sub-questions. All but one of the main questions
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were closed-ended questions, with most asking respondents to choose between the answers
“Yes”, “No” and “Do not know.” Most sub-questions were also closed-ended, although respon-
dents were given opportunities to add comments to clarify their answers. Respondents were
requested to provide sources for their responses where possible.
Following survey completion, we exported the full dataset from REDCap to Microsoft Excel
for data cleaning, resolution of queries and descriptive analyses. As part of data cleaning, we
initially reviewed the full dataset to identify instances where different respondents from the
same country had provided conflicting answers to survey questions. Discrepant responses
were resolved by accepting the majority response and/or the response supported by a valid
source. In cases in which there was no majority response, or where no sources were men-
tioned, or we could not determine the correct answer to the question, we consulted with the
Hep-Nordic study group participant(s) from the relevant country. Given the frequency with
which stakeholders contradicted each other in their survey responses, we decided to analyse
the discrepancies for inclusion in the overall study findings.
All descriptive analyses were performed in Microsoft Excel 2016 (version 15.26). For analy-
sis purposes, we combined hepatitis patient groups and drug user groups into “civil society
organisations”. We analysed partial responses and “Do not know” responses as incorrect and
counted these as discrepancies. We analysed responses by individual country, survey domain
and stakeholder group. It was possible for respondents to be asked different numbers of sub-
questions depending on which answers they provided to the main questions; therefore, calcu-
lations vary for each country. We excluded responses to one primary question and one sub-
question from the final analysis due to a demonstrated lack of understanding of the intended
meaning of those questions.
According to the regional representative of the Danish data protection agency and the Bar-
celona Institute for Global Health (ISGlobal), this study was not considered to be research on
human subjects and therefore did not require ethical review or approval. We stored all data on
secure servers in the Capital Region of Denmark and the data were managed according to
Danish regulations.
Results
Of the 17 stakeholders who were identified and invited to participate in the study, 14 agreed to
participate, yielding an 82% response rate.
National coordination
Respondents from three of the five countries (Finland, Iceland and Norway) reported that a
written national strategy for viral hepatitis exists, approved by the national government
(Table 1). One of the three countries (Iceland) reported the existence of an action plan
for strategy implementation. Stakeholders from the two countries without national written
strategies (Denmark and Sweden) reported that they do not have plans to develop strategies.
While Finland and Iceland reported that their national strategies address only HCV, Norway
reported having a strategy that addresses all forms of viral hepatitis. Both Finland and Norway
reported that CSOs were consulted during the development of the strategy.
Survey respondents from countries with strategies were further asked if those strategies
addressed several specific elements of the recommended public health response to viral he-
patitis, including public awareness, surveillance, vaccination, transmission prevention, diag-
nostic testing, linkage to care, treatment, and HIV co-infection. Respondents’ answers to these
questions suggest that Norway’s strategy is the most comprehensive, as it was reported to
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Table 1. NATIONAL COORDINATION.
Denmark Finland Iceland Norway Sweden
Question Answer Discrepancy Answer Discrepancy Answer Discrepancy Answer Discrepancy Answer Discrepancy
Written national viral
hepatitis strategy
approved by the national
government
No1 Yes Yes2 N/A Yes3 N/A Yes No No No
exclusively for viral
hepatitis
N/A N/A Yes N/A Yes N/A Yes No N/A N/A
addresses hepatitis A
virus
N/A N/A No N/A No N/A Yes No N/A N/A
addresses hepatitis B
virus
N/A N/A No N/A No N/A Yes No N/A N/A
addresses hepatitis C
virus
N/A N/A Yes N/A Yes N/A Yes No N/A N/A
addresses hepatitis D
virus
N/A N/A No N/A No N/A Yes No N/A N/A
addresses hepatitis E
virus
N/A N/A No N/A No N/A Yes No N/A N/A
addresses raising
public awareness
N/A N/A Yes N/A Yes N/A Yes No N/A N/A
addresses surveillance N/A N/A Yes N/A Yes N/A Yes No N/A N/A
addresses vaccination N/A N/A No N/A No N/A Yes No N/A N/A
addresses prevention
of transmission
generally
N/A N/A Yes N/A Yes N/A Yes No N/A N/A
addresses prevention
of transmission via
injecting drug use
N/A N/A Yes N/A Yes N/A Yes No N/A N/A
addresses prevention
of transmission in health
care settings
N/A N/A No N/A No N/A Yes Yes N/A N/A
addresses diagnostic
testing
N/A N/A Yes N/A Yes N/A Yes Yes N/A N/A
addresses linkage to
care for people
diagnosed with viral
hepatitis
N/A N/A Yes N/A Yes N/A Yes No N/A N/A
addresses treatment
and care for people
diagnosed with viral
hepatitis
N/A N/A Yes N/A Yes N/A Yes No N/A N/A
addresses HIV co-
infection
N/A N/A No N/A Yes N/A No No N/A N/A
developed in
consultation with civil
society groups
N/A N/A Yes N/A No N/A Yes No N/A N/A
Action plan on how the
strategy will be
implemented
N/A N/A No N/A Yes N/A No No N/A N/A
Development of national
viral hepatitis strategy is
planned
No Yes N/A N/A N/A N/A N/A N/A No Yes
National goal for the
elimination of HCV
No No No Yes Yes N/A No No No No
National disease register
for HCV infection
No Yes No Yes Yes No Yes Yes Yes Yes
(Continued)
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encompass all elements except for HIV co-infection. Only the Iceland strategy was reported to
address HIV co-infection.
The only study country reported to have a national goal regarding the elimination of HCV
was Iceland.
Stakeholders from Iceland, Norway and Sweden reported that their governments, or gov-
ernment-related institutions, have national disease registries for HCV.
Stakeholders from Finland, Norway and Sweden responded affirmatively when asked “Does
your government employ a geographic information system (GIS) in its disease monitoring activi-
ties?”, although only the Swedish stakeholders indicated that viral hepatitis data are included in
analyses.
Hepatitis C prevention
A survey question asked if the government or any government-related institution had con-
ducted or funded another organisation to conduct public awareness/education campaigns
relating specifically to HCV prevention since January 2015. All countries with the exception of
Denmark answered “yes” (Table 2).
All five countries reported that opioid substitution therapy (OST) is available to the general
public in all parts of their countries. Respondents from Denmark, Finland and Norway indi-
cated that needle and syringe programmes (NSPs) are available to the general public in all
parts of their countries. Respondents from Iceland and Sweden indicated that these services
are available only in some parts of their countries. It was reported that people may participate
in NSPs anonymously in all countries except Sweden, where registration is required. Sweden
was reported to be the only country with a minimum age requirement for participating in
NSPs.
Denmark and Iceland reported that OST is provided in prison facilities in all parts of their
countries. Finland, Norway and Sweden reported that OST is provided in prison facilities in
some parts of their countries. None of the respondents reported the provision of NSPs in
prison facilities. Only Denmark reported that bleach and other materials for sterilising inject-
ing equipment are available in prison facilities in all parts of their countries. Norway reported
that while the materials may be provided in some facilities, they are not available in all parts of
the country.
Respondents in every country except Sweden reported that clean needles and syringes can
be legally obtained outside of NSP programmes.
Table 1. (Continued)
Denmark Finland Iceland Norway Sweden
Question Answer Discrepancy Answer Discrepancy Answer Discrepancy Answer Discrepancy Answer Discrepancy
Government employs
geographic information
system (GIS) for disease
monitoring
No Yes Yes, but does
not include
viral hepatitis
data
Yes No No Yes, but does
not include
viral hepatitis
data
No Yes,
includes
viral
hepatitis
data
Yes
1. There are guidelines from the Danish Societies of Infectious Diseases and Gastroenterology & Hepatology, but there is no written national strategy from the National
Board of Health.
2. Strategy was released at the time of the survey. Answers in the table reflect information captured from a survey respondent with knowledge of the strategy.
3. Respondents provided examples of two different national strategies (one from the government and one from the TraPHepC project). For the purpose of this analysis,
the answers captured reflect the TraPHepC project strategy and therefore, discrepancies were not observed.
https://doi.org/10.1371/journal.pone.0190146.t001
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Hepatitis C testing and linkage to care
Stakeholders from four countries reported that national guidelines identified certain groups
whose members should be routinely offered HCV testing, with Finland being the only country
without such guidelines (Table 3). All four countries with national guidelines recommend that
Table 2. HEPATITIS C PREVENTION.
Denmark Finland Iceland Norway Sweden
Question Answer Discrepancy Answer Discrepancy Answer Discrepancy Answer Discrepancy Answer Discrepancy
Public awareness/
education campaigns
held specifically on HCV
prevention (since
January 2015)
No Yes Yes Yes Yes No Yes No Yes Yes
Opioid substitution
therapy available to the
general public in all parts
of the country
Yes No Yes No Yes Yes Yes No Yes No
Needle and syringe
exchange programmes
available to the general
public in all parts of the
country
Yes Yes Yes Yes No–only
in some
parts
No Yes No No–only in
some parts
No
General public can
participate anonymously
in needle and syringe
exchange programmes
Yes No Yes No Yes No Yes No No–
Registration
is required
Yes
Minimum age for
participating in needle
and syringe exchange
programmes
No No No Yes No No No No Yes No
Age at which general
public can participate in
needle and syringe
exchange programmes
N/A N/A N/A Yes N/A N/A N/A N/A 181 No
Opioid substitution
therapy programmes
provided in prison
facilities in all parts of
the country
Yes No No–only
in some
parts
Yes Yes Yes No–only
in some
parts
Yes No–only in
some parts
Yes
Needle and syringe
exchange programmes
provided in prison
facilities in all parts of
the country
No–not
anywhere
Yes No–not
anywhere
Yes No–not
anywhere
No No–not
anywhere
Yes No–not
anywhere
Yes
Bleach and other
materials for sterilising
injecting equipment
provided in prison
facilities in all parts of
the country
Yes Yes No–not
anywhere
Yes No–not
anywhere
No No–only
in some
parts
Yes No–not
anywhere
Yes
Clean needles and
syringes legally available
to people who inject
drugs outside of needle
and exchange
programmes (e.g. at
pharmacies)
Yes Yes Yes Yes Yes No Yes Yes No Yes
1. Policy recently updated, minimum age lowered from 20 to 18 years.
https://doi.org/10.1371/journal.pone.0190146.t002
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people who received blood or blood products before a certain date, PWID, and people living
with HIV should be routinely offered HCV testing (Fig 1). In two countries (Iceland and Nor-
way), national guidelines identify current prisoners, migrants and men who have sex with men
as groups that should be routinely offered HCV testing. Only one country’s guidelines (Den-
mark) make this recommendation for health care workers. No country’s guidelines call for
HCV testing to be routinely offered to people in certain age groups, or to pre-surgery patients,
sex workers, former prisoners, or military personnel.
Table 3. HEPATITIS C TESTING AND LINKAGE TO CARE.
Denmark Finland Iceland Norway Sweden
Question Answer Discrepancy Answer Discrepancy Answer Discrepancy Answer Discrepancy Answer Discrepancy
Which groups are identified in the
national guidelines as groups that should
routinely be offered HCV testing?
pre-surgery patients No No N/A1 N/A No No No No No No
all people in certain age groups No No N/A N/A No No No No No No
people who received blood or blood
products before a certain date
Yes Yes N/A N/A Yes No Yes No Yes No
people who inject drugs Yes No N/A N/A Yes No Yes No Yes Yes
people living with HIV Yes Yes N/A N/A Yes No Yes No Yes Yes
people who are currently incarcerated No Yes N/A N/A Yes Yes Yes No No Yes
former prisoners No Yes N/A N/A No No No No No No
sex workers No Yes N/A N/A No No No No No No
migrants No Yes N/A N/A Yes Yes Yes No No Yes
military personnel No No N/A N/A No No No No No No
healthcare workers Yes Yes N/A N/A No No No No No No
men who have sex with men No Yes N/A N/A Yes Yes Yes No No Yes
People in all parts of the country have
access to free HCV testing services
Yes Yes Yes Yes DNK Yes Yes No Yes No
People in all parts of the country have
access to anonymous HCV testing services
No No No Yes No No No Yes No Yes
Rapid HCV testing is available in
community settings
No Yes No Yes Yes Yes No No No Yes
There is a clear linkage-to-care mechanism Yes No No Yes Yes No Yes No Yes Yes
1. Respondent indicated that there are no official national HCV testing guidelines in Finland. Therefore, these answers are not currently reflected in the table.
https://doi.org/10.1371/journal.pone.0190146.t003
Fig 1. Groups that should be routinely offered HCV testing according to national guidelines.
https://doi.org/10.1371/journal.pone.0190146.g001
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Stakeholders from every country except Iceland indicated that people in all parts of their
countries have access to free HCV testing. Respondents from all five countries reported that
access to anonymous HCV testing services is not available in all parts of their countries.
Respondents from Iceland were the only ones to report that rapid HCV testing is available in
community settings.
Respondents from every country except Finland reported the existence of a clear linkage-
to-care mechanism to ensure that people who are diagnosed with HCV are referred directly to
a physician who can manage their care.
Hepatitis C treatment
Finnish stakeholders were the only ones who reported not having national HCV treatment
guidelines (Table 4). Participants representing all five of the study countries reported the pro-
vision of publicly funded direct-acting antiviral (DAA) treatment for patients with chronic
HCV infection. According to stakeholders from Iceland, there has been unrestricted access to
DAA treatment since 2016. Other study countries limit access to DAA treatment, for instance,
to those who have a minimum fibrosis level or by setting patient quotas.
In all countries except Sweden, patients with chronic HCV infection have the option of
being treated in various non-hospital settings. None of the study countries give patients the
option of being treated by general practitioners, though in Denmark, Iceland and Norway,
patients have the option of being treated in addiction/opioid substitution clinics or harm
reduction centres. Danish, Icelandic and Swedish respondents reported that HCV patients in
their countries have the option of being treated in prison.
Stakeholders from four countries indicated that HCV treatment can be obtained from
healthcare providers in all parts of their countries. While that is not the case in Iceland,
patients there are eligible to receive free transportation to Reykjavik for care if needed. At the
time of the survey, none of the countries reported the availability of HCV treatment in prison
facilities in all parts of their countries.
Discrepancies between responses from representatives of different
stakeholder groups
The incidence of stakeholder disagreement by country and survey domain ranged from 0 for
the “national coordination” domain in Iceland to 100% for the “testing and linkage to care”
domain in Finland, with 50% or more disagreement for the majority of domains across the
countries (Fig 2). None of the individual stakeholders from any of the countries gave correct
answers to all of the survey questions. On average, representatives of CSOs had a higher pro-
portion of incorrect responses to survey questions (39%) than representatives of government
or medical societies (data not shown).
Discussion
This study sought to provide insight into the policy response to HCV in the Nordic countries,
where transmission among PWID contributes greatly to the HCV disease burden. Although
these are among the wealthiest countries in the world, and are well recognised for their respon-
sive health systems, our study suggests that the Nordic region as a whole has not consistently
expressed its full commitment to tackling the HCV epidemic at the policy level. There are gaps
in relation to the existence of national viral hepatitis strategies and national HCV treatment
guidelines, as well as uneven efforts to address HCV prevention, testing and linkage to care.
The provision of publicly funded DAA treatment puts all five countries in a good position to
pursue global HCV elimination targets; yet other policy shortcomings have the potential to
Policy responses to hepatitis C in the Nordic countries
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Table 4. HEPATITIS C TREATMENT.
Denmark Finland Iceland Norway Sweden
Question Answer Discrepancy Answer Discrepancy Answer Discrepancy Answer Discrepancy Answer Discrepancy
National
guidelines for
the treatment of
HCV
Yes Yes No1 Yes Yes No Yes No Yes No
Guidelines
published by
European
Association for
the Study of the
Liver (EASL) or
other
international
clinical
association are
adopted as
national
guidelines
No No N/A N/A No No No No No No
Guidelines
published by
World Health
Organization
(WHO) are
adopted as
national
guidelines
No No N/A N/A No No No No No No
National
government
develops its
own national
guidelines
Yes Yes N/A N/A Yes2 Yes No No No Yes
National
medical society
develops its
own national
guidelines
Yes Yes N/A N/A No No Yes No Yes Yes
Other
publishers of
guidelines
N/A N/A N/A N/A TraPHepC
project
Yes N/A N/A N/A N/A
Most common
HCV genotype
in country
Genotype 1 Yes Genotype 3 Yes Genotype 3 No Genotype
3
No Genotype
1
Yes
Duration of
recommended
first-line
treatment
regimen for this
genotype
12 weeks Yes 12 weeks Yes 12 weeks No Other3 No 12 weeks Yes
Second most
common HCV
genotype in
country
Genotype 3 Yes Genotype 2 Yes Genotype 1 No Genotype
1
No Genotype
3
Yes
Duration of
recommended
first-line
treatment
regimen for this
genotype
12 weeks Yes - Yes 12 weeks No 12 weeks Yes 12 weeks Yes
(Continued)
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Table 4. (Continued)
Denmark Finland Iceland Norway Sweden
Question Answer Discrepancy Answer Discrepancy Answer Discrepancy Answer Discrepancy Answer Discrepancy
Publicly funded
direct-acting
antiviral (DAA)
treatment
provided to
chronic HCV
patients in your
country
Yes No Yes No Yes No Yes No Yes Yes
Only patients
above a certain
fibrosis level are
eligible for
treatment
Yes No Yes No No No Yes4 No Yes Yes
Only a
limited number
of patients can
be treated
within a certain
time period or a
certain
geographical
area
Yes Yes Yes No No No No No No No
People who
currently drink
alcohol are not
treated
No Yes Yes Yes No No No No No No
People who
injected drugs
in the past are
not treated,
even if they are
not currently
injecting drugs
No No No No No No No No No No
People who
currently inject
drugs are not
treated
Yes Yes Yes Yes No No No No No Yes
People who
injected drugs
in the past are
only treated if
they have
abstained from
injecting drugs
for a specified
period of time
No Yes Yes Yes No No No No No Yes
People who
currently inject
drugs or
injected drugs
in the past are
treated only if
they are
receiving
opioid
substitution
therapy
Yes No Yes Yes No No No No No No
(Continued)
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undermine progress in all five countries. Furthermore, not all key stakeholders within the
study countries have the same information regarding which policies are actually in place.
With the inclusion of a goal addressing viral hepatitis in the Sustainable Development
Goals in 2016, the United Nations signalled that governments need to collectively step up the
global response to this group of diseases. [28] Later the same year, WHO made the charge to
governments more concrete by introducing the first Global health sector strategy on viral
Table 4. (Continued)
Denmark Finland Iceland Norway Sweden
Question Answer Discrepancy Answer Discrepancy Answer Discrepancy Answer Discrepancy Answer Discrepancy
HCV patients
have the option
of being treated
in non-hospital
settings
Yes Yes Yes Yes Yes Yes Yes No No Yes
HCV patients
have the option
of being treated
in general
practitioner
clinics
No No No No No No No No No No
HCV patients
have the option
of being treated
in addiction/
opioid
substitution
clinics or harm
reduction
centres
Yes Yes No No Yes Yes Yes No No No
HCV patients
have the option
of being treated
in “other”
settings
Yes Yes Yes Yes Yes No No No Yes Yes
“Other”
settings in
which HCV
patients have
the option of
being treated
Prisons, in
collaboration
with the
hospital
No Private practice
gastroenterologists,
self-paid by patients
Yes Prisons Yes N/A N/A Prisons Yes
HCV treatment
can be obtained
from healthcare
providers in all
parts of the
country
Yes Yes Yes Yes No Yes Yes No Yes Yes
HCV treatment
is provided in
prisons in all
parts of the
country
No Yes No No No Yes No Yes No Yes
1. There are currently no official national guidelines for the treatment of HCV. Treatment recommendations made by leading gastroenterologists are published in the
Finnish medical journal. Establishing national guidelines, including treatment, are priorities for the new hepatitis C strategy published in November 2016.
2. Guidelines from the national government and from the TraPHepC Project were both reported in the survey.
3. Treatment is offered only to patients below 40 years of age. If HCV RNA is not positive after 4 weeks, the treatment is extended to 12 weeks
4. Yes” for genotypes 2 and 3 and “No” for genotype 1.
https://doi.org/10.1371/journal.pone.0190146.t004
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hepatitis. [22] The Action plan for the health sector response to viral hepatitis in the WHO Euro-
pean Region, which is aligned with the Global Strategy, adds targets for European countries,
such as “50% of people living with chronic HBV and HCV infections are diagnosed and aware
of their condition”. [3] Governments must implement multiple types of public health interven-
tions on a national scale in order to progress towards HCV elimination, as reflected in the
“continuum of viral hepatitis services” described in the Global Strategy. National policies can
greatly influence the extent to which the necessary interventions are brought to scale in all
areas of the HCV continuum, including prevention, testing, linkage to care and treatment, as
well as prevention of reinfection among people who are cured, which the Action Plan has
established as a priority for all European countries.
In light of their abundant resources and strong public health infrastructure, [29] the Nordic
countries are in a position to demonstrate global leadership on HCV elimination. High levels of
HCV transmission among PWID in the Nordic region provide both a moral and practical imper-
ative for governments to act decisively, and the effectiveness of new DAA treatment regimens
makes the full elimination of HCV much more feasible than it was even five years ago. Our study
findings highlight policy gaps across the HCV continuum and suggest that all of the Nordic coun-
tries should consider strengthening their policy responses to HCV in one or more ways. With nei-
ther written national strategies nor plans to develop such strategies, the governments of Denmark
and Sweden in particular demonstrate a lack of commitment to HCV elimination.
One unexpected finding from our study was the widespread lack of consensus among
respondents about their countries’ policy responses to HCV. This raises the question of
whether there is sufficient communication among stakeholders regarding the formulation or
implementation of policies. CSOs appeared to be lacking more information than other stake-
holder groups, which is problematic, as WHO recognises the involvement of affected commu-
nities as an important component of strong national responses to viral hepatitis. [22]
Current best practices call for PWID to have access to comprehensive, evidence-based mul-
tidisciplinary harm reduction services, especially OST and sterile injecting equipment, along
with community-based support services. [30] The Action plan for the health sector response to
viral hepatitis in the WHO European Region recognises the centrality of harm reduction as a
component of the Region’s viral hepatitis elimination efforts by calling for the following mile-
stone to be reached by 2018: “Policies developed and implemented supporting comprehensive
harm reduction programmes, including risk reduction communication, needle and syringe
programmes, and opioid substitution therapy or ‘pharmacotherapy of opioid dependence’
Fig 2. Incidence of stakeholder disagreement by country and survey domain.
https://doi.org/10.1371/journal.pone.0190146.g002
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including in the community and in prisons”. [3] Our finding that the availability of harm
reduction services varies widely across the Nordic countries is thus notable. While all countries
reported the availability of OST to the general public, other key services are limited, as are ser-
vices in prison facilities. For example, Sweden–the Nordic country with the largest number of
patients receiving HCV treatment–has several policies that limit access to harm reduction ser-
vices. It is the only study country requiring a minimum age to access NSPs, the only one where
clean needles/syringes cannot be purchased legally at pharmacies by PWID, and the only one
that does not allow anonymous participation in NSPs. In contrast, a respondent from Finland
reported that needles and syringes can be purchased without a medical prescription at most
pharmacies in the country, and that “pharmacies play a key role in needle and syringe provi-
sion in areas [without] health counselling centres”.
The 2016 guidelines from the European Association for the Study of the Liver (EASL) state
that all patients with HCV infection “must be considered for treatment”, [16] and in 2017,
EASL publicly noted that this recommendation is intended to apply to PWID alongside other
patients. [31] Our study findings confirm that most of the Nordic countries are at the forefront
of HCV treatment efforts through the use of DAAs to attain high cure rates in those with
chronic HCV infection, including PWID, as all countries provide publicly funded DAA treat-
ment. For example, in 2016, Iceland initiated a nationwide campaign whereby all viraemic
patients were offered DAA treatment free of charge and without restrictions, and the country
launched an intensive HCV testing and treatment effort in prisons. In other Nordic countries,
however, treatment availability for prison populations is inconsistent, which is problematic, in
light of what is known about the HCV burden in prisons worldwide. [11]
National HCV programmes must have reliable epidemiological and service coverage infor-
mation in order to determine which interventions need to be intensified in which populations
and locations. [22] Our study revealed potential opportunities for harmonisation between data
from geographic information systems and national disease registries, and for improved disease
surveillance and service delivery monitoring.
Limitations
Our analysis may be limited by the survey sample, as not all stakeholder groups were evenly rep-
resented. The small sample size precludes viewing this study as anything more definitive than
an exploratory effort to inform stakeholders’ discussions about the public health responses to
HCV in the five study countries. It is possible that the use of English for the survey may have
resulted in a lack of clarity or in questions being interpreted in different ways by different
respondents; in fact, two questions were ultimately eliminated from the analysis because of con-
fusion among respondents about their meaning. Some of the questions that were asked may
have been more difficult to answer in an informed way for respondents outside of government
than for government respondents. Although all survey respondents were told that what they
shared would be reported anonymously, the small size of the national stakeholder community
in all five study countries raises the question of whether some respondents may not have per-
ceived themselves to be truly anonymous. It is possible that concerns about the perceptions of
other stakeholders may have influenced their answers to survey questions. In addition, this anal-
ysis may not reflect policy changes that occurred after the study participants submitted their
survey responses and indeed Finland has since approved a viral hepatitis strategy.
Conclusions
Our study, the first to investigate the policy response to HCV in all of the Nordic countries,
has highlighted areas in which policy-makers in these countries should consider strengthening
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their responses. In all countries, we observed widespread disagreement between key stakehold-
ers regarding which policies are in place. The study findings may inform efforts in other coun-
tries where PWID are disproportionately affected by HCV. Stakeholder alignment and an
established elimination goal with an accompanying strategy and implementation plan should
be recognised as the basis for coordinated national public health efforts to achieve HCV elimi-
nation in the Nordic region and elsewhere.
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